These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 30733722)

  • 1. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very Low Numbers of CD4
    Copsel S; Wolf D; Kale B; Barreras H; Lightbourn CO; Bader CS; Alperstein W; Altman NH; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1788-1794. PubMed ID: 29751114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
    Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
    Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors.
    Barreras H; Copsel SN; Bader CS; Ding Y; Wolf D; Cash C; Stacey CJ; Benjamin C; Seavey MM; Wolf J; Jasuja RR; Pfeiffer B; Hill GR; Komanduri KV; Jurecic R; Malek TR; Levy RB
    Transplant Cell Ther; 2023 May; 29(5):341.e1-341.e9. PubMed ID: 36804930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
    Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
    Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.
    Colonna L; Florek M; Leveson-Gower DB; Sega EI; Baker J; Smith AT; Negrin RS
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1557-65. PubMed ID: 23921175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.
    Mavers M; Simonetta F; Nishikii H; Ribado JV; Maas-Bauer K; Alvarez M; Hirai T; Turkoz M; Baker J; Negrin RS
    Front Immunol; 2019; 10():1624. PubMed ID: 31379829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
    Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
    Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
    Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
    Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
    Pillai AB; George TI; Dutt S; Strober S
    Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
    Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
    J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
    Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
    Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
    Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
    Front Immunol; 2020; 11():181. PubMed ID: 32117306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
    Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
    Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
    Giorgini A; Noble A
    J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse.
    Bremm M; Huenecke S; Lehrnbecher T; Ponstingl E; Mueller R; Heinze A; Bug G; Quaiser A; Kapinsky M; Brehm C; Bader P; Schneider G; Klingebiel T; Koehl U
    J Immunol Methods; 2011 Oct; 373(1-2):36-44. PubMed ID: 21839739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation.
    Lim DG; Koo SK; Park YH; Kim Y; Kim HM; Park CS; Kim SC; Han DJ
    Transplantation; 2010 Apr; 89(8):928-36. PubMed ID: 20305583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
    Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.